Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296634 · ClinicalTrials.gov registry record · Phase 1
H5 Vaccine Alone or With Adjuvant in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 600
- Enrollment target
NCT00296634: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00296634 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 600 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (900% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00296634, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 600 participants
- Enrollment target
Study Summary
This randomized, controlled, double-blinded, dose-ranging, Phase I-II study in 600 healthy adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational inactivated influenza A/H5N1 virus vaccine when given alone or combined with aluminum hydroxide. A secondary goal is to guide selection of vaccine dosage levels for expanded Phase II trials based on reactogenicity and immunogenicity profiles. This dose optimization will be applied to both younger and older subject populations in subsequent studies. Subjects who meet the entry criteria for the study will be enrolled at one of 4 study sites and will be randomized into one of 8 groups to receive 2 doses of influenza A/H5N1 vaccine containing 3.75, 7.5, 15, or 45 mcg of HA with or without aluminum hydroxide adjuvant by intramuscular injection. Participants may be involved in study related procedures for up to 8 months.
Interventions
- DRUG Aluminum hydroxide
- BIOLOGICAL Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00296634 record still lists
NCT00296634 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (900% higher).
The record links to 0 conditions, and to 2 interventions - of which Aluminum hydroxide is the first listed.
NCT00296634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00296634 about?
NCT00296634 is a clinical study titled "H5 Vaccine Alone or With Adjuvant in Healthy Adults". This randomized, controlled, double-blinded, dose-ranging, Phase I-II study in 600 healthy adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational inactivated influenza A/H5N1 virus vaccine when given alone or combined ...
What is the current status of trial NCT00296634?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 600 participants. The study started on 2006-03. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00296634?
The interventions under investigation include: Aluminum hydroxide (DRUG), Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00296634?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00296634's enrollment target sits among peer trials
600 27th of 2000 higher than 1,973 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia